Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,596 across all filing types
Latest filing 2024-03-12 Investor Presentation
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
关于举行2023年度网上业绩说明会的通知
Investor Presentation Classification · 90% confidence The document is a notice about holding the 2023 annual performance explanation meeting (业绩说明会) online, scheduled for March 15, 2024. It invites investors to participate and submit questions in advance. The text does not contain actual financial data or results but is an announcement of an upcoming event related to the company's annual performance. This matches the description of an Investor Presentation (IP) or a Call Transcript (CT) if it were the transcript. However, since this is a notice about the meeting and not the transcript or presentation itself, it is best classified as an Investor Presentation (IP) type document, as it relates to a detailed presentation for investors focusing on financials and strategy. The document length is short and it is not a report publication announcement or regulatory filing. Therefore, the best fit is Investor Presentation (IP).
2024-03-12 Chinese
东莞证券股份有限公司关于特一药业集团股份有限公司2023年度内部控制自我评价报告的核查意见
Audit Report / Information Classification · 95% confidence The document is titled as an internal control self-evaluation report for the year 2023 of a company, with detailed descriptions of internal control systems, evaluation criteria, and the results of the evaluation. It includes a verification opinion from a sponsoring institution (东莞证券股份有限公司) regarding the internal control report. The content focuses on internal control evaluation, governance, risk management, and compliance with regulatory requirements. It does not contain full financial statements or comprehensive financial performance data typical of an Annual Report (10-K) or Interim Report (IR). It is not a brief announcement or a certification letter but a detailed report on internal control self-evaluation. This fits best with the category of Audit Report / Information (AR), which includes audit reports, applied accounting principles, and internal control evaluations, excluding full annual reports. The document length (6449 characters) supports it being a full report rather than a short announcement. Therefore, the classification is AR with high confidence. FY 2023
2024-03-07 Chinese
关于向商业银行申请集团综合授信额度并对子公司提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 特一药业集团股份有限公司 regarding the application for a comprehensive credit facility from commercial banks and the provision of guarantees to its subsidiaries. It details the credit limits, guarantee amounts, terms, and the board's approval of the matter. There are no financial statements or detailed financial performance data presented, nor is this a transcript, report, or presentation. The document is a formal announcement of financing arrangements and guarantees, which fits the category of Capital/Financing Update (CAP). The document length is under 5,000 characters and contains substantive content about financing, so it is not a mere report publication announcement or regulatory filing. Therefore, the classification is CAP with high confidence.
2024-03-07 Chinese
董事会对独立董事独立性评估的专项意见
Board/Management Information Classification · 95% confidence The document is a statement from the board regarding the independence of the company's independent directors, referencing regulatory rules about independent directors and their independence evaluation. It is a specialized opinion on director independence, not a full report, financial statement, or announcement of voting results. It does not contain financial data or meeting results. This fits best under Board/Management Information (MANG), which includes announcements related to board matters such as director independence assessments.
2024-03-07 Chinese
内部控制审计报告
Regulatory Filings
2024-03-07 Chinese
关于变更公司电子邮箱的公告
Regulatory Filings Classification · 100% confidence The document is a short announcement regarding the change of the company's investor relations email address. It contains no financial data, no report content, and no regulatory or voting information. It is a general regulatory announcement about contact information update. The document length is only 422 characters, indicating it is a brief notice rather than a full report. Therefore, it fits best under Regulatory Filings (RNS).
2024-03-07 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.